Protein-Protein Interactions at the Adrenergic Receptors

Susanna Cotecchia*1,2, Laura Stanasila1 and Dario Diviani1

1Département de Pharmacologie et de Toxicologie, Université de Lausanne, Switzerland, and 2Dipartimento di Fisiologia Generale e Ambientale, Università di Bari, Italy

Abstract: The adrenergic receptors are among the best characterized G protein-coupled receptors (GPCRs) and knowledge on this receptor family has provided several important paradigms about GPCR function and regulation. One of the most recent paradigms initially supported by studies on adrenergic receptors is that both βarrestins and G protein-coupled receptors themselves can act as scaffolds binding a variety of proteins and this can result in growing complexity of the receptor-mediated cellular effects. In this review we will briefly summarize the main features of βarrestin binding to the adrenergic receptor subtypes and we will review in more detail the main proteins found to selectively interact with distinct AR subtype. At the end, we will review the main findings on oligomerization of the AR subtypes.

Keywords: Adrenergic receptor subtypes, signaling complexes, arrestins, receptor oligomerization.

INTRODUCTION

The adrenergic receptors (AR) mediate the functional effects of catecholamines, like epinephrine and norepinephrine, by coupling to different signaling pathways modulated by G proteins. The adrenergic receptor family includes nine different gene products, three β (β1, β2, β3), three α (α1a, α1b and α1d) and three α2 (α2A, α2B and α2C) receptor subtypes.

The adrenergic receptors, and in particular the β2AR, are among the best characterized G protein-coupled receptors (GPCRs) and knowledge on this receptor family has provided several important paradigms about GPCR function and regulation.

One of the most recent paradigms initially supported by studies on adrenergic receptors is that G protein-coupled receptors can act as scaffolds binding a variety of proteins and this can promote multiple signaling events which results in growing complexity of the receptor-mediated cellular effects (reviewed in ref. [1]).

In the late 1980s, the first protein found to interact with the β2AR, beyond G proteins, was βARK1 (BAR kinase 1) [2], discovered as the first member of the G protein-coupled receptor kinase family (GRK) [3]. The ability of GRK2 and 3 to selectively interact with the agonist-bound form of the β2AR was a crucial observation to identify their role in homologous desensitization.

Soon after the discovery of GRKs, it became apparent that β2AR desensitization required also the interaction of an arrestin protein with the phosphorylated receptor [2, 4]. This interaction resulted in both receptor-G protein uncoupling and receptor endocytosis into clathrin-coated pits [5].

In the last ten years, an important function of βarrestins has come to light as scaffolds for a growing number of signaling proteins thus coordinating complex signal transduction events [6]. In particular, it is well established that βarrestins are scaffolds for components of the mitogen activated protein kinase (MAPK) cascade thus mediating MAPK activation induced by various GPCRs.

This seminal work encouraged the search for novel protein-protein interactions at several GPCRs with the aim of identifying previously unappreciated signaling mechanisms that might represent new targets of pharmacological intervention. A number of approaches have been followed to identify novel proteins interacting with the receptors, including yeast two-hybrid screen using cytosolic portions of the receptors as bait, pull-down or in vitro overlay assays using purified proteins, co-immunoprecipitation of receptor-protein complexes from recombinant or native cells, FRET (fluorescence resonance energy transfer) or BRET (bioluminescence resonance energy transfer) technology in cells. These studies resulted in the identification of a variety of proteins interacting with the adrenergic receptors, several of them in a receptor subtype selective pattern. A major challenge faced by these studies has been to identify the functional implications of these interactions. Some interacting proteins have been found to either promote or impair receptor-mediated signaling whereas others are involved in receptor trafficking or endocytosis.

Among the protein-protein interactions found to regulate GPCR function, receptor oligomerization has been extensively investigated in recent years [7]. Both homo- and hetero-oligomerization have been reported for different adrenergic receptor subtypes using different experimental approaches. This phenomenon seems to have implications in different aspects of receptor function, including its pharmacological profile, signaling, trafficking or endocytosis.

The canonical interactions of the adrenergic receptors with G proteins, GRKs and βarrestins have been extensively studied and exhaustively reviewed elsewhere [8, 9]. In this review we will briefly summarize the main features of βarrestin binding to the adrenergic receptor subtypes and we will review, more in detail, a number of proteins found to selectively interact with distinct AR subtype. At the end, we will review the main findings on oligomerization of the AR...
subtypes. Considering the large number of studies on protein-protein interactions at GPCRs, our review might not systematically include all published data.

The direct interaction of GPCRs with selected partners has recently emerged as a new mechanism of receptor signaling and regulation. Since these mechanisms might be specific for distinct receptors or cell types, the study of these interactions has interesting implications in pharmacology and drug development.

**βARRESTIN INTERACTION WITH THE AR SUBTYPES**

The well established crucial role played by βarrestin1 and 2 in coordinating a variety of signaling networks might imply that these proteins can form macromolecular complexes with virtually any GPCR.

The interaction of βarrestins with the β2AR has been extensively characterized both at functional and molecular level using different approaches including in vitro binding of purified proteins, co-immunoprecipitation, BRET or FRET, βarrestin translocation, as well as confocal microscopy to assess colocalization of the proteins [6, 8, 9]. The β2AR displays a pattern of interaction with βarrestins defined as "Class A" characterized by greater affinity for βarrestin 2 than 1 and a short-lived receptor/βarrestin complex leading to rapid receptor recycling after endocytosis. The interaction with βarrestins is important in mediating β2AR-induced activation of ERK1/2 (see references in [6]).

In contrast to the significant amount of data on the β2AR, much less is known about the interaction of βarrestins with other AR subtypes. The interaction of the β1AR with βarrestin is much weaker than that displayed by the β2AR subtype and this seems to correlate with the resistance of the β1AR to undergo agonist-induced endocytosis [10]. However, the β1AR can transactivate the epithelial growth factor (EGF) receptor in a βarrestin-dependent mechanism and this effect might have implications in cardioprotection [11]. This is suggested by a recent study reporting that recruitment of βarrestin to the C-tail of the β1AR is required for maintaining the β1AR/EGF receptor complex.

Also the β2AR does not seem to interact with βarrestins as suggested by two lines of evidence. First, the β2AR is resistant to agonist-induced endocytosis [12]. Second, the ability of the β2AR to activate MAPK is independent from βarrestin binding since its activation does not result in βarrestin recruitment to the plasma membrane [13].

The interaction of βarrestin with the α2AR was initially investigated measuring the effect of overexpressed βarrestin on receptor endocytosis [14]. Overexpression of βarrestin significantly increased the endocytosis of the α2a and α2c-AR, but had no effect on the α2A-AR suggesting poor interaction of this receptor subtype with βarrestin. The lack of βarrestin interaction with the α2A-AR was confirmed by in vitro studies measuring the binding of purified βarrestin to peptides derived from the 3i loop of the three α2-AR subtypes [15].

The interaction of the α1a and α1b-AR subtypes with βarrestin has been investigated by a recent study using different approaches including co-immunoprecipitation, endocytosis and confocal microscopy [16]. Whereas the α3b-AR displayed robust agonist-induced endocytosis, the α1b-AR did not. The results from both co-immunoprecipitation experiments and βarrestin translocation assays indicated that the agonist-induced interaction of the α1b-AR with βarrestin was much weaker than that of the α3b-AR. The interaction of βarrestin with the α1b-AR has not been directly explored so far.

Altogether these findings indicate that the interaction pattern of βarrestin with distinct AR subtypes is divergent and correlates with differences in the internalization properties of the receptors. Overall, despite the large number of studies on the β2AR, a lot remains to be explored concerning the implications of βarrestin in adrenergic receptor function and regulation.

**PROTEINS INTERACTING AT THE β1AR**

The first cytoplasmic proteins found to interact selectively with the β1AR subtype were endophilins 1/2/3, also called SH3p4/p8/p13 [17]. This SH3 domain-containing protein family bound the proline-rich third intracellular (i3) loop of the β1AR in both pull-down assays and yeast two hybrid screens. The primary effect of this interaction was to promote agonist-induced internalization of the receptor and to modestly decrease its coupling to Gs. Intriguingly, a similar proline-rich sequence is found in the i3 loop of the β1 or α2A-AR, but these receptors do not bind endophilins. The mechanism through which endophilin might regulate receptor coupling and internalization is not known, but it could include steric hindrance or allosteric modulation of G protein and arrestin binding.

A second class of proteins selectively interacting with the β1AR are proteins containing the PDZ (PSD-95/Disc-large/ZO-1 homology) domain which recognizes the extreme C-terminus of the target protein. The β1AR possesses a type I PDZ binding sequence, E-S-K-V, at the end of its C-tail and it has been shown to bind the postsynaptic protein PSD-95 [18]. This protein is abundant in brain where it co-localizes with the β1AR in postsynaptic densities. This interaction was found in a yeast two-hybrid screening using the β1AR C-terminus as bait and it markedly attenuated β1 internalization, while having no impact on the receptor desensitization or signaling to adenylyl cyclase. Association with PSD-95 could also facilitate the linkage of the β1 to NMDA glutamate receptors, known to be regulated by adrenergic signaling in the brain, and, more in general, to facilitate targeting of the β1AR subtype at synapses. Other studies demonstrated that the interaction with PSD-95 is negatively regulated by agonist treatment, through phosphorylation of the receptor by GRK5, thus allowing receptor internalization [19].

A second PDZ domain containing protein interacting with the β1AR is membrane-associated guanylate kinase inverted-2 (MAGI-2), a multidomain scaffold protein, also known as S-SCAM (synaptic scaffolding molecule). The first PDZ domain of MAGI-2 binds with high affinity to the β1AR C-tail, as demonstrated by overlay and pull-down techniques [20]. The β1AR/MAGI-2 interaction occurred constitutively in cells, but it was further enhanced by isoproterenol treatment. It favored agonist-induced internalization
of the receptor, an effect opposite to the one observed for PSD-95, another PDZ-domain protein [18]. MAGI-2 also promoted β1AR association to β-catenin, a known MAGI-2 partner.

A third PDZ domain containing protein binding the β1AR is GIPC (Gs-interacting protein-interacting protein, C-terminus) [21]. This interaction decreased ERK1/2 activity stimulated by the β1AR, through a Gi-dependent process, with no observable effects on the Gs-mediated cAMP accumulation or on receptor internalization. One last example of a PDZ domain-mediated interaction with the β1AR is CAL (Cystic Fibrosis Transmembrane Conductance Regulator-Associated Ligand), found by pull-down techniques to interact with the ESKV sequence of the β1AR [22]. Overexpression of CAL, a protein localized in the Golgi apparatus, reduced surface expression of the receptor, a process competitively reversed by PSD-95.

GPCRs can indirectly activate Ras through the Gβγ subunits of the G protein that can recruit c-Src, Grb-Sos and PI3 kinase. The β1AR was the first GPCR for which a direct interaction with a Ras-GEF (GTP exchange factor), CNrasGEF, had been described [23]. CNrasGEF bound the ESKV sequence of the β1AR through its PDZ domain and mediated isoproterenol-induced Ras activation.

The importance of the PDZ binding sequence in the C-tail of the β1AR was highlighted by findings obtained expressing the receptor in mouse cardiac myocytes [24]. In these cells, stimulation of the β1AR increases the contraction rate, whereas the β2AR has a biphasic effect with an initial increase followed by a decrease mediated by receptor coupling to Gi. In addition, whereas the β1AR undergoes endocytosis, the β1AR does not. Interestingly, the mutation of the PDZ binding sequence of the β1AR enabled both receptor internalization and coupling to Gi thus providing evidence that differences in the interaction with PDZ containing proteins might dictate the distinct physiological effects induced by the two βAR subtypes.

Each of the four PDZ domain containing proteins above described, although binding to the same sequence of the β1AR, exerted different effects both on receptor trafficking and signaling. It is noteworthy that these four proteins do not share the same tissue distribution, PSD-95 and MAGI-2 being almost exclusively found in the brain, whereas GIPC and CNasGEF being predominantly expressed in the heart. A recent proteomic screen aimed at providing an exhaustive view of PDZ-mediated interactions at the β1AR, confirmed the association with PSD-95, MAGI-2, GIPC and CAL, and identified two novel ones, SAP97 and MAGI-3 [25]. MAGI-3 co-expression profoundly impaired β1AR-mediated ERK1/2 activation.

To assess the GPCR selectivity of these interacting proteins a recent study used a library of 59 GPCR C-tails, among which those of the β1 and β2AR, in a pull-down assay [26]. This approach identified the lysosomal targeting protein GASP1 (G protein-coupled receptor-Associated Protein) as a potential interacting partner of the β2AR, but this finding was not explored further. GASP1 had been previously identified in a yeast two-hybrid screen as a protein interacting with the C-tail of the δ opioid receptor and shown to interfere with the post-endocytic sorting of the receptor. It was later discovered that GASP1 is member of a family of ten proteins displaying some sequence similarities whose functional implications are still largely unknown (reviewed in [27]). Whereas GASP1 can interact with several GPCRs other proteins of this family have been shown to modulate transcription. Considering these two important features, the GASP proteins might represent a promising area of investigation in the GPCR field.

Another protein recently shown to interact with the β2AR and influence it’s trafficking is golgin-160 which is a ubiquitously expressed Golgi membrane protein [28]. Golgin-160, whose function in Golgi structure is unknown, can interact with the third intracellular loop of the β2AR and its depletion in cells leads to a significantly reduced cell surface expression of the receptor.

An interesting interaction was recently found between the β2AR and the adaptor protein 14-3-3 epsilon both in recombinant cells and heart [29]. The receptor/14-3-3 complex can compete with the interaction occurring between 14-3-3 epsilon and the voltage-gated potassium channel, Kv11.1, and this might represent a mechanism involved in adrenergic regulation of cardiac repolarization. Whereas the wild type β2AR inhibits potassium current, a receptor mutant lacking its interaction with 14-3-3 can activate it. This is a fascinating finding highlighting the role of multiple protein interactions in fine tuning of the physiological effects mediated by the adrenergic receptors on cardiac rhythms.

Another finding highlighting the potential functional impact of different signaling complexes in heart cells concerns the interaction of the β1 and β2AR subtypes with phosphodiesterases (PDE) [30]. Whereas the β2AR forms a complex with β-arrestin and the PDE4D5 isoform, the β1AR can directly interact with the PDE4D8 isoform and the agonist can dissociate this complex. Both the receptor and PDE4 are regulated in a complex manner by the cAMP/PKA cascade and binding of PDE4D to the β2AR might allow for the control of cAMP levels in proximity of the receptor.

PROTEINS INTERACTING AT THE β2AR

PDZ domain-mediated interactions are also known to occur at the C-tail of the β2AR, which includes the type I PDZ-binding C-terminal sequence D-S-L-L. The first protein found to interact specifically with this sequence of the β2AR, but not with β1AR, was NHEF1 (Na+/H+ Exchanger Regulatory Factor 1), also named EBP50 (ERM- Binding Protein 50) [31]. This protein contains two PDZ domains and regulates the activity of the Na+/H+ exchanger type 3 (NHE3). In addition, NHERF factors represent a well established link between ERM (Ezrin-Radixin-Moesin) proteins and specific polytopic membrane proteins [32]. The β2AR/NHERF interaction might play a role in the receptor-mediated regulation of cellular pH. Typically, an increase of intracellular cAMP levels inhibits NHE3 activity (via PKA-mediated phosphorylation of NHERF), but the stimulation of the β2AR potentiates it. This is probably due to the fact that binding of the β2AR to NHERF relieves the NHERF-mediated inhibition of NHE3.

NHERF can also be a link between the β2AR and other proteins which interact with NHERF, such as the platelet-
derived growth factor (PDGF) receptor [33] and cystic fibrosis transmembrane conductance regulator (CFTR) [34]. Whereas PDGF receptor-mediated signaling is potentiated by its interaction with NHERF, the formation of the β2AR/NHERF complex might regulate PDGF receptor function. A macromolecular complex composed of the β2AR, CFTR and NHERF was shown to form in human airway epithelia and this complex might represent an important mechanism underlying the β2AR-stimulated increase of CFTR activity.

In addition to mediating these functional effects of the β2AR, the interaction with NHERF seems to play a direct role in receptor trafficking. The β2AR is a member of class A GPCRs, being characterized by rapid agonist-induced endocytosis and recycling back to the plasma membrane. It was demonstrated that disruption of either NHERF binding to the β2AR or NHERF binding to the actin cytoskeleton (mediated by NHERF/ERM interaction) caused missorting of endocytosed β2AR to the degradation pathway and prevented its recycling [35]. Actin depolymerization had a similar effect, implying that anchoring of the receptor to the actin cytoskeleton through NHERF and ERM proteins ensures its proper trafficking following endocytosis. A similar role for NHERF in directing the recycling of several other GPCRs was subsequently documented [32].

Another protein that associates with the distal part of the β2AR C-tail is NSF (N-ethylmaleimide-sensitive factor) [36]. Despite lacking PDZ domains, NSF also recognizes the extreme C-terminal sequence D-S-L-L and its association with the receptor is increased upon agonist treatment. NSF binding to the β2AR was shown to be required for both receptor internalization and recycling, but it is unclear whether a competition between NSF and NHERF binding to the receptor takes place and how this process is regulated.

The role of the PDZ binding sequence in the β2AR was validated in cardiac myocytes by the same group which investigated the β1AR-mediated effects on contraction rate [37]. Deletion of the PDZ binding motif in the β2AR abolished its coupling to Gi resulting in higher contraction rate, in contrast to the effect observed for the β1AR, where a similar mutation promoted Gi coupling and decreased contraction [24]. In agreement with previous findings, the mutated β2AR lacking interaction with NHERF was unable to recycle back to the plasma membrane. The experimental design did not allow to discriminate between NSF- and NHERF1-mediated effects.

Stimulation of the β2AR raises intracellular cAMP levels leading to activation of protein kinase-A (PKA). The functional connection between the β2AR and PKA prompted the investigation on potential interactions between this receptor and PKA-anchoring proteins, or AKAPs. The first AKAP found to bind the β2AR was AKAP250, also known as gravin. Association of gravin to the receptor was increased upon agonist treatment [38] and involved the C-terminal portion of the receptor [39]. Suppression of gravin expression using an antisense strategy disrupted receptor resensitization and impaired its association to GRK2, βarrestin and clathrin, suggesting that gravin might serve as a scaffold bringing together kinases, phosphatases and proteins of the endocytic machinery.

Another AKAP, AKAP79, directly and constitutively interacts with the β2AR and promotes its phosphorylation by PKA, which is obligatory for MAPK activation by the receptor [40]. The anchored PKA was further shown to phosphorylate GRK2 enabling its translocation to the membrane and subsequent phosphorylation of the β2AR [41]. Thus, AKAP79 is involved in the process of β2AR desensitization and internalization through the clathrin-dependent pathway. The molecular determinants of the receptor interaction with AKAPs were unfortunately not finely mapped and the question of the specificity of this interaction among adrenergic receptor subtypes has not been addressed yet.

An interaction of the β1AR with the adaptor protein Grb2 has also been reported [42]. This interaction was not identified through unbiased screening, but specifically tested based on the observation that insulin abolishes catecholamine response by stimulating tyrosine phosphorylation of the β2AR. This phosphorylation creates an SH2 site on the β2AR which induces Grb2 binding to the receptor at Tyr250/254 thus leading to receptor-G protein uncoupling. Grb2 binding to the receptor was increased upon cell treatment with insulin and promoted also receptor internalization [43].

Interesting interactions have been found between the β2AR and ion channels involved in the regulation of membrane excitability. The β2AR was found to directly interact with the voltage-gated calcium channel Cav1.2 in hippocampal neurons [44]. A complex containing the β2AR, the Cav1.2, G protein, an adenylate cyclase, PKA and the PP2A phosphatase might represent a mechanism ensuring a specific and highly localized signaling process.

It is well known that β2AR and PKA activation can increase BKCa activity in neurons, smooth muscle cells and other excitable cells. Recent findings indicate that the β2AR can interact with calcium sensitive K+ channels (BKCa) in a complex containing the receptor, BKCa and AKAP79 [45]. Thus, the β2AR might interact with both the Cav1.2 calcium channel and the BKCa calcium sensitive K+ channel, and these interactions might enable a highly localized control of membrane excitability.

A recent study reports a fascinating finding concerning the interaction between the β2AR and two proteins, the von Hippel-Lindau tumor suppressor protein (pVHL)-E3 ligase complex and the dioxygenase EGLN3 [46]. It is known that in response to hypoxia there is a decreased expression of β2AR in heart attributed to high levels of catecholamines whereas the β2AR abundance increases suggesting a direct regulation of this receptor by oxygen. The metallo-sensory enzyme dioxygenase EGLN3 transduces O2-responsive signals through modifications of target proteins. Thus, the interaction of EGLN3 with the β2AR results in hydroxylation of Pro382 and Pro395 of the receptor. After hydroxylation of the β2AR, pVHL-E3 ligase is recruited triggering ubiquitylation of the β2AR and its degradation. This finding highlights the broadness and complexity of protein-protein interactions that can be explored to understand receptor function and regulation.
PROTEINS INTERACTING AT THE β3AR

The β3AR subtype was cloned several years after the other βAR subtypes and its distribution seems to be restricted to adipose tissue, skeletal and smooth muscles. For these reasons little is known to date about the specific interactions of this AR subtype. One cytoplasmic partner has been identified, namely the tyrosine kinase Src, that can bind through its SH3 domain to the polyproline region in the third intracellular loop and the C-tail of the receptor [13]. The direct binding of Src of the β3AR seems required for ERK1/2 activation by the receptor. Previous reports from the same group had demonstrated an involvement of Src in MAPK activation by the β3AR, but this effect was mediated by the interaction of Src with βarrestin. As mentioned above, direct Src binding to the β3AR occurred through its SH2 domain on the phosphotyrosine Tyr350. The paucity of data regarding β3AR interactions leaves open an entire field of investigation in the signaling of this receptor.

PROTEINS INTERACTING AT THE α1A AR

Few interactions have been shown to occur selectively at the α1A AR subtype. Yet, this receptor contains a PDZ binding sequence G-E-E-V at its C-terminus that can be expected to give rise to PDZ-domain mediated interactions. An early report, at the issue of a yeast two-hybrid screen, identified the type III PDZ domain of nNOS (neuronal nitric oxide synthase) as a potential α1A AR interacting protein [47]. However, co-immunoprecipitation studies, while confirming this interaction, failed to highlight selectivity for the α1A AR subtype since all three α1AR subtypes could be co-immunoprecipitated with nNOS and this even when they were lacking their C-terminus. This interaction appeared to be without apparent physiological implications in spite of the known role of NO in the regulation of blood pressure and of nNOS as local metabolic inhibitor of α1AR-mediated vasoconstriction.

Another study reported that mammalian tolloid (mTLD) could interact with the α1AAR [48]. The CUB5 domain of mTLD, a zinc-finger matrix metalloprotease of the astacin family, interacted with α1AAR C-tail in a yeast two hybrid screen. The interaction was specific for the α1AAR and the binding region on the receptor could be narrowed down to a sequence of 37 aminoacids. Overexpression of mTLD reduced the number of cell surface receptors without affecting total receptor level or affinity when transiently expressed in HEK293 cells. mTLD also appeared to facilitate calcium signalling evoked by phenylephrine. No mechanism was proposed to account for the observed phenomena.

Interesting prospects were opened by the report of the direct interaction between RGS2 (Regulator of G protein Signaling 2) and the third intracellular loop of the α1A AR [49]. RGS proteins are well characterized inhibitors of heterotrimeric G protein function, acting as GAPs (GTPase activating proteins) to increase the rate of GTP hydrolysis at Go subunits and thus terminate signaling. More than 30 RGS proteins have been identified so far, but many RGS proteins can non-selectively bind to and inhibit Goα/Go and Gαq11 in reconstituted systems, suggesting that other factors may regulate their specificity for a particular signaling pathway. RGS2 was found to interact with the α1A AR third intracellular loop confirming what previously shown for other Gq-coupled receptors, namely the cholinergic muscarinic M1, M3 and M5 receptors [50] and it inhibited agonist-induced inositol phosphate responses without affecting ligand binding.

PROTEINS INTERACTING AT THE α1B AR

Two main interacting partners were pulled out of a yeast two-hybrid screen for the α1B AR: the μ2 (or AP50) subunit of the clathrin adaptor complex AP2 [51] and ezrin, a member of the ERM protein family [52]. The AP2 complex is part of the endocytic machinery mediating clathrin-dependent endocytosis of membrane proteins and is recruited to agonist-activated GPCRs through the intermission of βarrestins. Interactions of the AP50 subunit are dependent upon a YxxF motif present in the cargo protein. However, in the case of the α1B AR, binding of AP50 relied on a basic stretch of eight arginines in the proximal C-tail of the receptor. Direct association of the α1B AR to AP50 contributed to the agonist-induced internalization of the receptor as demonstrated by the fact that a receptor mutant lacking the AP50 binding motif was delayed in internalization. The presence of the eight arginine motif in the C-tail of a GPCR is not common, which rules out the hypothesis that direct AP50 interaction is a common mechanism for clathrin-mediated endocytosis. Interestingly, this feature is shared by the α1A AR, which contains a stretch of seven positive charges in its C-tail, but no studies were undertaken using this receptor subtype.

In addition to AP50, the same yeast two-hybrid screen identified ezrin as a potentially direct binding partner of the α1B AR [52]. Ezrin belongs to the ERM family of proteins, primarily described as linkers between membrane proteins and cortical actin. Ezrin was also shown to be involved in the remodelling of the actin cytoskeleton, in the modulation of Rho signaling (by binding to Rho GTP dissociation inhibitor (GDI) and through direct association to several Rho GTP/GDP exchange factors (GEFs) as well as in anchoring of PKA. Ezrin interactions with polytopic membrane proteins generally occur through the adaptor proteins EBP50 (NHERF1) and E3KARP (NHERF2), but direct contacts were also described between ezrin and proteins such as the Na+/H+ exchanger type 1 (NHE1) and podocalyxin. So far, a role for the ERM proteins in GPCR trafficking was inferred from the finding that NHERF1 binding to some GPCRs promoted their recycling, depending on its binding to ERM proteins. The α1B AR is the first GPCR for which a direct interaction with ezrin has been found. Disruption of this interaction by overexpression of a dominant negative mutant of ezrin inhibited receptor recycling after internalization, as did actin depolymerization. Thus, the involvement of ERM proteins in GPCR trafficking, through either a direct or indirect interaction with the receptor, might represent a general paradigm for the regulation of GPCR trafficking.

Intriguingly, ezrin and AP50 shared the same binding site on the α1B AR C-tail, consisting in the eight arginines stretch positioned after the putative palmitoylation site. In pulldown experiments the binding domain of ezrin and that of AP50 competes with each other for the same binding site of the receptor C-tail (unpublished data). How these events are
regulated within the cell is a matter that awaits further inquiry.

Another protein, the receptor for globular "Heads" of c1q (gC1qR), was reported to interact with the same arginine-rich sequence in the α1s and the α1dAR [53]. gC1qR is a glycoprotein mainly displaying intracellular localization, but also present on the surface of macrophages and T cells through anchoring to β-integrin, where it is part of a complement receptor. No functional relevance was demonstrated for its interaction with the α1b or α1dAR.

PROTEINS INTERACTING AT THE α1dAR

The α1dAR was for a long time a "poor relative" to the other α1AR subtypes, the α1a and α1b, because poorly expressed at the cell surface in heterologous systems, probably because of its long N-terminus. This peculiarity hampered the investigation of its potential interactions with other proteins. Apart from the above mentioned interaction with gC1qR, whose functional implications are unknown [53], another interacting partner of the α1dAR was α-syntrophin [54]. α-syntrophin, a protein containing one PDZ domain and two PH (pleckstrin homology) domains, specifically recognized the C-tail of the α1dAR, but not that of the α1a or α1b, in the yeast two-hybrid assay. The PDZ domains of syntrophin isoforms α, β1 and β2, but not γ1 or γ2, could interact with the α1dAR C-tail. The α1dAR possesses the C-terminal sequence E-T-D-I, which mutation impaired syntrophin binding to the receptor and markedly decreased norepinephrine-induced inositol phosphate accumulation. This mutation also dramatically decreased receptor expression levels. Interestingly, syntrophins seemed to interact equally well with intracellular or surface-expressed α1dAR receptors. Taken altogether these results suggested that syntrophins act to maintain the stability of the α1dAR through a PDZ-mediated interaction.

PROTEINS INTERACTING AT THE α2AR SUBTYPES

The three α2AR receptor subtypes (α2A, α2B and α2C) are coupled to the Gi/o family of heterotrimeric G proteins, and hence to the inhibition of adenylyl cyclase and voltage sensitive calcium channels, and to the activation of potassium channels. They are differently expressed in various tissues including the basolateral membrane of polarized renal epithelial cells where differences in the targeting and trafficking of the three subtypes have been found. The proper basolateral retention of the α2A receptor subtypes is dependent upon the integrity of their third intracellular loop, a finding which prompted the search for partners interacting with this region of the receptors. A gel overlay strategy using in vitro translated i3 loops of the α2AR receptors highlighted the interaction of the zeta isoform of 14-3-3-proteins [55]. 14-3-3 proteins are ubiquitous and involved in the regulation of a number of signaling pathways, among which the Ras/MAPK cascade. 14-3-3 interacted preferentially with the α2A and α2B than with the α2C. A detailed study of the sequence requirements for this interaction at the α2AAR did not identify a single linear motif suggesting that a three dimensional structure in the i3 loop is needed for 14-3-3 binding [56].

An important binding partner of all three α2AR subtypes is spinophilin [57, 58]. This interaction was specifically tested with the rationale that spinophilin is enriched beneath the basolateral membrane of MDCK cells. Spinophilin binding to α2AAR was enhanced by agonist treatment and the region responsible for binding was loosely mapped to the N- and C-terminal ends of the i3 loop [56]. Interaction with spinophilin contributed to the cell surface stabilization of the α2BAR subtype, a receptor that displays the unique property of being first randomly delivered to both apical and basolateral side of the cell, with a much faster apical versus basolateral turnover which ends up in its accumulation on the basolateral side. Apical delivery of a spinophilin subdomain extended the half-life of the α2BAR in this region; furthermore, agonist-stimulated internalization of the receptor was accelerated in fibroblasts derived from spinophilin knock-out mice [59]. Presumably, similar effects could occur at the other two α2AR subtypes. An explanation of this effect came from the finding that spinophilin blocks GRK2 association to the α2BARs thus inhibiting receptor endocytosis [60].

Spinophilin was also found to interact with other GPCRs, including the α1bAR, as well as with the N-terminal domain of RGS proteins (RGS1, 2, 4 and 16) which participates in GPCR recognition [60, 61]. Thus spinophilin might represent an interesting functional bridge between RGS and α2AR subtypes that don't bind RGS, like the α1bAR. In fact, it has been found that spinophilin increases the RGS2-induced inhibition of the α1bAR calcium response. In support of this finding, a constitutively active α1bAR mutant did not bind spinophilin and was resistant to inhibition by RGS2. Similar resistance to RGS2 inhibition was found to occur in spinophilin knock-out cells. These data offer a glimpse into a potentially more general regulatory mechanisms of GPCR function by spinophilin.

The most recent protein found to interact with α2ARs is ubiquitin carboxyl-terminal hydrolase-L1 (Uch-L1), a protein associated with Parkinson disease [62]. Uch-L1 binds preferentially to the α2AAR subtype and its overexpression inhibits the receptor-induced activation of MAPK. This interaction might have implications in the neuroprotective effect of α2ARs which needs to be further investigated.

OLIGOMERIZATION OF THE ADRENERGIC RECEPTORS

Findings in the last decade challenged the widely held view of GPCRs functioning as monomeric units [7]. Early biochemical studies showing higher molecular weight receptor bands migrating in SDS-PAGE gels, stabilized by crosslinking, suggested that adrenergic receptors might form oligomers. Afterwards, co-immunoprecipitation of differentially tagged GPCRs or functional complementation of pairs of co-expressed inactive receptor mutants provided stronger evidence in favor of GPCR oligomers. The widespread use of biophysical techniques such as FRET or BRET between GPCRs carrying the appropriate pair of fluorescent/bioluminescent labels suggested oligomerization of a variety of GPCRs. Each technique employed has its own shortcomings: whereas co-immunoprecipitation cannot rule out indirect interactions, energy transfer techniques can only certify that the two partners are in close proximity, not necessarily
in immediate contact. Therefore, whether receptor oligomerization involves direct interactions among receptor monomers versus their increased proximity in micro-domains of the cell membrane cannot be unequivocally demonstrated. Despite the fact that the precise molecular events are not fully understood, the term of GPCR oligomerization is largely accepted to indicate the existence within the cell membrane of macromolecular complexes formed by two or more receptor monomers. It is important to highlight that most studies have been performed in recombinant cells overexpressing the receptors with very few examples of oligomerization occurring in physiological systems.

Homo-Oligomerization

Within the adrenergic receptor family, the β2AR was the first member for which homo-oligomerization was described, using co-immunoprecipitation of epitope-tagged receptors [63]. BRET technology was then adapted for the purpose of showing the existence of receptor oligomers at the cell surface and of quantitatively assessing the extent of oligomerization [63, 64]. Homo-oligomerization was therefore demonstrated for the β2AR [63, 64], β1AR [65], α1a and α1b [66, 67], α1d [67], α2a and α2c [68], and for the α2b [69] AR subtypes.

Whereas the stoichiometry of these complexes is hard to assess with either biochemical or biophysical methods used so far, the structural architecture of receptor oligomers has been addressed by some studies using computational, pharmacological and biochemical approaches. Two types of receptor-receptor interaction have been proposed, involving either lateral contact or domain swapping. A model was proposed for a β2AR dimer where the two receptor monomers swapped helices V and VI [70]. Other studies pointed at helices I and VII [66] or I/II and III/IV [71] as the probable interface for receptor-receptor contact in the case of the α1b AR. Neither the C-terminal tail of the α2cAR nor its glycosylation state or the presence or absence of a glycolphorin dimerization motif GxXXG in the transmembrane domains affected its oligomerization [66]. This was in contrast with the previous report of Hébert et al., showing that helix VI containing the GxxXGxxG motif was responsible for oligomerization of the β2AR [63].

The functional implications of AR homo-oligomerization have been explored by several studies. Preventing receptor association has been technically difficult with few exceptions. In the case of the β2AR, a peptide derived from helix VI was shown to disrupt dimerization and its use was demonstrated to impair isoproterenol-stimulated cAMP production by the β2 AR [63] implying that β2 oligomers would be the functional form of the receptor.

Among the functional implications of AR homo-oligomers, different studies investigated their localization within the cell. BRET studies suggested that β2AR oligomers are present at the plasma membrane [64]. Biotinylation with a membrane-impermeable showed expression of α1a, α1b and α1d homodimers at the cell surface [67]. Moreover, homo-oligomerization of the β2AR seems to be a prerequisite for its plasma membrane targeting [72]. In fact, the peptide derived from helix VI of the β2AR, which blocks receptor oligomerization, prevented normal targeting of the receptor to the plasma membrane. These results imply that receptor oligomers form as early as the stage of their synthesis in the endoplasmic reticulum and that oligomerization influences their maturation and trafficking ability from then onwards. Indeed, co-expression with a recycling-defective mutant diverted wild type β2AR from normal recycling to the plasma membrane to the proteolytic degradative pathway [73]. Similar data were obtained for the α2AR subtype; when co-expressed with a mutant deficient in cell surface targeting, the wild type α2AR remained trapped in the endoplasmic reticulum [69].

A matter of debate has been the regulation of the oligomeric status of GPCRs by ligands. One among the first reports indicated that agonist binding could increase the amount of β1AR dimers [63], corroborated by BRET data [64]. In contrast, agonist treatment had no apparent effect on the oligomerization of α1AR subtypes [66, 67]. Furthermore, constitutively active or non-functional α1bAR mutants displayed the same propensity to oligomerize as the wild type receptor [66], indicating that the activation state of the receptor is irrelevant for this process.

Hetero-Oligomerization

Different AR subtypes are often co-expressed in the same cells and cross-talk among them can occur. Various studies addressed the hypothesis that hetero-oligomerization could account for cross-talk effects. A number of interactions between different AR subtypes or between ARs and more distantly related GPCRs have been reported (Table 2).

The adrenergic receptor subtypes seem to display selectivity of interaction and hetero-oligomers do not form for any two receptor combination. Within the AR family, the following main hetero-oligomers have been found: β1/β2 [74], β2/β1 [75], α1b/α1a and α1b/α1d, (but not α1a/α1d) [66, 67], α1b/β2 [66], α1d/β2 [77], α2a/α2c [68], α2b/β1 [78] and α2c/β2 [79].

In addition, the following main combinations have been described between AR subtypes and other GPCRs: β2AR/olfactory receptor [80], β2AR/δ opioid and β2AR/κ opioid [81], βAR/AT1 angiotensin II [82], β2AR/5-HT4 serotonin [83], β3AR/EP1 prostaglandin [84], β2AR/CB1 cannabinoid [85], α2b/μ opioid [86] and α2b/δ opioid [87]. Very recently a macromolecular complex including the β2AR, Gs, PKA, adenylyl cyclase and the AMPA glutamate receptor, mGluR1, has been described [88].

Hetero-oligomerization was found to have various functional effects upon the behavior of individual receptors, ranging from regulated targeting to modified pharmacological, signaling or trafficking profile in recombinant systems. Co-expression of the α1AR with the α1bAR [76] or the β2AR [77] was able to rescue surface expression of the α1bAR, the majority of which is intracellular when expressed alone in various cell lines. A similar phenomenon was already observed for the GABA-B receptor and for the calcitonin/adrenomedullin receptor, both receptors needing hetero-dimerization in order to be properly targeted to the plasma membrane. Interestingly, the interaction with the α1bAR modified the pharmacological profile of the α1aAR which looses its affinity for its selective ligand BMY7378 when it is co-expressed with the α1bAR. The α1b/α1d dimer
behaues as a single functional entity with increased response to norepinephrine relative to either monomer alone. The α1b/AR receptor was long supposed to be little expressed in the heart, as its selective ligand BMY7378 could detect only minimal levels of the receptor. However, these findings should be considered in a new light, given that the α1b and α1d/AR subtypes co-exist in this tissue and the pharmacological profile of the α1d/AR might be different than expected because of oligomerization.

Hetero-dimerization of the β2/AR with the α2C/AR, which is normally poorly expressed in recombinant cells, increased the expression at the cell surface and ERK1/2 signaling of the α2C/AR [79]. Coexpression of the α2C/AR with more than twenty-five GPCRs revealed that only the β2/AR induced this effect. Coexpression of the β2/AR with the olfactory receptor (M71) also promoted the cell surface localization of this receptor which is often co-expressed with the β2/AR in olfactory neurons [80]. Again, only the β2/AR among the AR subtypes had this effect.

Beyond its effect on receptor targeting to the cell surface, hetero-oligomerization seems to have an impact on various aspects of receptor trafficking and signaling. For example, several studies have shown that receptor monomers can mutually influence their endocytosis pattern. Whereas the α1b/AR undergoes agonist-induced internalization, the α1d/AR does not. However, when the two AR subtypes were co-expressed forming heterodimers, the endocytosis of each monomer could be triggered by stimulation of the other [66]. Co localization of the two monomers could be seen in endocytic vesicles suggesting that the α1b/α1d dimers remained stable throughout the endocytosis process.

Strikingly, in β1/β2 heterodimers, the internalization of the β1/AR within the complex was inhibited. Furthermore, β2/AR-induced ERK activation was equally blocked by co-expression of β1/AR [78]. Similar results were also found for the β2/β1 heterodimer [79] in which β2/AR internalization was impaired. The β1/AR is resistant to agonist-promoted endocytosis and, like the β1/AR, acted as a dominant negative on β2/AR internalization.

In α2A/β1 heterodimers, stimulation of the α2A/AR triggered the internalization of the β1/AR [78]. In addition, the β1/AR within the heterodimer displayed altered pharmacology. In α2A/α2C heterodimers, the GRK-dependent phosphorylation and βarrestin recruitment at the α2A/AR, were inhibited [68].

Functional cross-talk was also described between the β2/AR and the opioid receptors (OR) that are coupled to stimulatory and inhibitory G proteins, respectively. Whereas in the β2/δ opioid dimer the β2/AR and δOR could facilitate the endocytosis of each other, in the β2/κ opioid dimer the internalization of the β2/AR was inhibited. Moreover, isoproterenol-induced MAPK activation was diminished in presence of κOR, showing that κOR acts as a dominant negative modulator of the β2/AR [81].

The same group explored the possible interaction between α2A/AR and opioid receptors that colocalize in neurons and affect the nociceptive response. The α2A/μ opioid could be isolated from recombinant cells as well as from primary neurons. In the α2A/μ opioid dimer the activation of each monomer increases G protein and MAPK signaling whereas the activation of both monomers decreases it [86]. In addition, when the receptors were expressed in a neuronal cell line the α2A/AR increased the δOR-mediated neurite outgrowth [87]. These results support the notion that α2A/AR and opioid receptors are synergic in spinal analgesia as also demonstrated by the decrease in morphine-induced analgesia in α2A−/− knock out mice. Thus, the physical association between the β2/AR and opioid receptors might explain their functional interaction.

Some interesting findings have been reported concerning the potential implications of βAR hetero-oligomerization with other GPCRs in native tissues. Whether in native tissues simultaneous synthesis of hetero-dimer partners can occur or different receptors are simply clustered in the same cell membrane compartment is not known.

In freshly isolated mouse cardiomyocytes, interesting effects were reported on contractility induced by angiotensin II (AgII) acting at AT1 receptor or isoproterenol acting at βAR [82]. Whereas the beta-blocker propranolol could inhibit the effect of AgII, the AT1 blocker valsartan inhibited that of isoproterenol. This transinhibitory effect of the two antagonists seemed related to inhibition of receptor coupling to its cognate G protein. Biochemical experiments on β2/AR and AT1 receptor expressed in HEK cells indicated that the two receptors could be co-immunoprecipitated thus suggesting that hetero-oligomerization of the two receptors could be the basis of their functional interaction in heart.

Hetero-oligomerization between the β2/AR (coupled to Gs) and the EP1 prostaglandin receptor (coupled to Gi) has been observed in airway smooth muscle [84]. In mouse tracheal rings, activation of the β2/AR induces muscle relaxation whereas stimulation of EP1 alone has no effect on contraction. However, stimulation of the EP1 receptor profoundly reduced the β2/AR-induced muscle relaxation and cAMP accumulation. The modulatory effect of EP1 receptor on the β2/AR might depend on the interaction between the two receptors which form heterodimers in airway smooth muscle cells.

Hetero-oligomerization has also been recently observed using BRET between the β2/AR and the CB1 cannabinoid receptor expressed in recombinant cells [85]. The formation of oligomers could be increased by a CB1 inverse agonist. Interestingly, co-expression of the two receptors resulted in increased localization at the cell surface and decreased constitutive activity of the CB1 receptor. Complex functional interactions on signaling between the two receptors have been found both in the recombinant system and in primary human trabecular meshwork (HTM) cells from the eye, a tissue in which the two receptors are natively co-expressed. Beyond mutual effects on ERK activation, activation of one receptor induces cross-desensitization of the other both in recombinant and HTM cells. This might be relevant in drug therapy since CB1 agonists and β2/AR antagonists can both reduce intraocular pressure.

Very recently, an elegant study demonstrated that the β2/AR can form a signaling complex with the GluR1 subunit of the AMPA glutamate receptor including also the trimeric Gs protein, adenylyl cyclase and protein kinase A [88]. This complex seems to be important to allow β2/AR-induced
phosphorylation of the GluR1 which results in increased GluR1 cell surface expression and current amplitudes.

CONCLUSIONS AND PERSPECTIVES

The AR subtypes have been found to interact with several proteins (Table 1) as well as to form homo and hetero-oligomers (Table 2). A critical approach in analyzing all these interactions should address a number of questions: is the interaction selective for one receptor or common to others? is it occurring in specific tissues? what are its functional implications? Addressing these questions is important to assess whether the interface of a receptor with a specific protein could be an interesting target of pharmacological intervention. For most interactions described at the

Table 1. Proteins Selectively Interacting with Distinct Adrenergic Receptor Subtypes

| Receptor | Partner | Binding Site | Functional Role | Refs. |
|----------|---------|--------------|-----------------|-------|
| α1a | endophilins | i3 loop (Pro-rich) | ↑ endocytosis | [17] |
| α1a | PSD-95 | C-tail (ESKV) | ↓ endocytosis; β2/NMDA receptor association | [18] |
| α1a | MAGI-2 | C-tail (ESKV) | ↑ endocytosis; association to β2-catenin | [20] |
| α2a | GIPC | C-tail (ESKV) | ↓ ERK activation | [21] |
| α2a | CAL | C-tail (ESKV) | ↓ cell surface expression | [22] |
| α2a | CNRasGEF | C-tail (ESKV) | Ras activation | [23] |
| α2a | MAGI-3 | C-tail (ESKV) | ↓ ERK activation | [25] |
| α2a | GASP | C-tail (ESKV) | unknown | [26] |
| α2a | golgin-160 | i3 loop | ↑ cell surface expression | [28] |
| α2a | 14-3-3 | phospho-sites | regulation of K⁺ current | [29] |
| α2a | PDE4D8 | unknown | regulation of cAMP levels | [30] |
| α2a | NHERF (or EBP50) | C-tail (DSLL) | regulation of NHE3; regulation of PDGF and CFTR activity; receptor recycling | [31] |
| α2a | NSF | C-tail (DSLL) | ↑ endocytosis | [36] |
| α2a | AKAP250 (gravin) | C-tail | ↑ endocytosis and resensitization; ↑ association to GRK2 and β-arrestin | [38] |
| α2a | AKAP79 | unknown | ↑ agonist-induced phosphorylation by GRK2 | [40, 41] |
| α2a | Grb2 | Tyr350/354 | ↑ endocytosis stimulated by insulin | [42] |
| α2a | Cav1.2 | unknown | ↑ Ca²⁺ current | [44] |
| α2a | BkCa | unknown | ↑ K⁺ current | [45] |
| α2a | pVHL, EGLN3 | Pro382/395 | O₂-induced ubiquitylation | [46] |
| α2a | Src | i3 loop and C-tail (Pro-rich) | ↑ ERK activation | [13] |
| α1b, α3b, α4b | nNOS | unknown | unknown | |
| α1b | tolloid | C-tail | ↓ surface expression | [48] |
| α1b | RGS2 | i3 loop (K219-S220-R238) | ↓ Gq signaling | [49] |
| α1b | AP50 | C-tail (8 Arg) | ↑ endocytosis | [51] |
| α1b | ezrin | C-tail (8 Arg) | ↑ recycling | [52] |
| α1b | spinophilin | i3 loop | ↓ Ca²⁺ signaling induced by RGS2 | [61] |
| α1b, α3b, α4b | syntrophins | C-term (ETD1) | stabilization of receptor at cell surface | [54] |
| α1b, α3b, α4b | gC1qR | C-tail (Arg) | unknown | [53] |
| α1b | 14-3-3 z | i3 loop | unknown | [55] |
| α1b, α3b, α4b | spinophilin | i3 loop | stabilization of receptor at cell surface; ↓ arrestin action | [55, 56] |
| α1b | Uch-L1 | i3 loop | ↓ MAPK activation | [62] |
AR subtypes, the answers to these questions are far from being answered.

Most of the interactions involving the AR subtypes have been found using various screening approaches (proteomic, yeast two hybrid or pull-down experiments) without a specific bias towards the interactions searched. In most studies, the investigation of the interactions has been performed in recombinant systems in which only a limited number of functional parameters common to all GPCRs can be explored, i.e. trafficking, signaling through known pathways, receptor pharmacology. This resulted in the identification of a number of proteins affecting receptor endocytosis (endophilins, PSD-95, MAGI-2, NSF, AKAP250, Grb2, AP50) and few others stabilizing receptor expression at the cell surface (golgin-160, spinophilin, syntrophin), favoring recycling (ezrin, NHERF) or regulating receptor coupling to G proteins (RGS2) (Table 1). Most of these interactions have been investigated only at a specific AR subtype with few exceptions. For example, the role of spinophilin in stabilizing receptor expression at the cell surface seems a property of all three α2 AR subtypes (α2A, α2B and α2C) [55, 56]. Spinophilin has been found to interact also with the α1B AR displaying, however, a different effect, i.e. the modulation of calcium signaling. Spinophilin certainly represents a protein of pharmacological interest which should be further investigated because of its well established role in targeting the α2-AR subtypes in polarized cells as well as in regulating their function.

It seems quite evident that proteins containing the PDZ domain can interact with both the β1 and β2AR. However, some PDZ domain containing proteins seem to display a selectivity towards either one of two receptors. For example, NHERF interacts with the C-tail of the β2AR, but not with the β1 [31]. PSD-95 interacts selectively with the β1AR being both proteins expressed in post-synaptic densities [18]. The interaction of PDZ proteins with the β1 and β2AR is also one of the few examples in which the functional implication has been investigated in a physiological system, i.e. mouse cardiac myocytes [24, 37]. Deletion of the PDZ binding motif in the β2AR abolished its coupling to Gi resulting in higher contraction rate, in contrast to the effect observed for the β1AR, where a similar mutation promoted Gi coupling and decreased contraction. Because of the functional relevance of these interactions, PDZ domain containing proteins might represent interesting targets to pharmacologically interfere with trafficking and signaling of either the β1 or β2AR. Recently, some success has been reported in designing small peptides blocking PDZ interactions [89]. In addition, despite the wide distribution of PDZ proteins, the overlapping expression of interacting partners might be restricted to some tissues and this could be functionally relevant. More detailed studies on this important family of proteins in the regulation of AR subtypes are required and might have important implications.

Beyond the various interacting proteins found using different screening approaches, few highly interesting

| Receptors | Trafficking | Pharmacology | Signaling | Refs. |
|-----------|-------------|--------------|-----------|-------|
| β2/β2     | no β1, endocytosis |              | ↓ β2, ERK activation | [74] |
| β2/β2     | no β2, endocytosis |              | no Gi/o coupling | [75] |
| β2/Olf    | ↑ Olf surface expression; co-endocytosis |              |            | [80] |
| β2/δOR    | co-endocytosis |              | ↓ β2, MAPK activation | [81] |
| β2/kOR    | no β2, endocytosis |              |            | [81] |
| β2/AT1    | trans-inhibition of endocytosis by antagonists |              | trans-inhibition of G protein coupling by antagonists | [82] |
| β2/5-HT4  |              |              |            | [83] |
| β2/EP1    |              | ↓ β2, smooth muscle relaxation |            | [84] |
| β2/CB1    | ↓ constitutive endocytosis of CB1; co-endocytosis | mutual effects on signaling; cross-desensitization | [85] |
| α1/α1b    | co-endocytosis | no change |            | [66] |
| α1/α1d    | ↑ α1d surface expression | ↓ α1d affinity for selective ligands | ↑ signaling | [67, 76] |
| α1/β2     | ↑ α1d surface expression; co-endocytosis |            |            | [77] |
| α2/α1     |              | ↓ α2, phosphorylation & β-arrestin recruitment | [68] |
| α2/β1     | co-endocytosis | altered β1 profile |            | [78] |
| α2/β2     | ↑ α2c, surface expression |            | ↑ α2c ERK signaling | [79] |
| α2/μOR    | ↑ signalling of each monomer |            | [86] |
| α2/δOR    |              | ↑ δOR neurite outgrowth |            | [87] |

Table 2. Hetero-Oligomerization of the Adrenergic Receptors
interactions have been found in elegant studies exploring the activity of the β2-AR in neuronal cells. The β2-AR was found to directly interact with the voltage-gated calcium channel Cav1.2 in hippocampal neurons [44]. It was reported that the β2-AR can also interact with calcium sensitive K+ channels (BKCa) in a complex containing the receptor, BKCa and AKA79 [42]. Thus, the β2-AR might interact with both the Cav1.2 calcium channel and the BKCa calcium sensitive K+ channel, and these interactions might enable a highly localized control of membrane excitability. Another recent study has reported that the β2-AR can form a signaling complex with the GluR1 subunit of the AMPA glutamate receptor including also the trimeric Gs protein, adenylyl cyclase and protein kinase A [88]. This complex might underlie the facilitating effect of β2ARs on long term potentiation mediated by AMPA receptors.

Altogether, these latter studies clearly indicate that the full elucidation of signaling events in time and space will depend on a much deeper understanding of the interactions among receptors and signaling molecules. Developing drugs acting at distinct receptor-protein interfaces might represent an approach to achieve more cell specific pharmacological effects. However, this field is still at an early stage because of the complexity of studying these events in physiological cell systems as demonstrated by the limited number of studies published so far. Therefore, the fine-tuning of GPCR activity by receptor-interacting proteins is a very promising area of investigation in which a lot remains to be explored [90]. Studies in recombinant systems can certainly provide some useful information, but the real challenge concerns the possibility of exploring the functional implications of a variety of interactions in different tissues and physiological conditions. Without these studies it will be difficult to assess which of these interactions are druggable.

ACKNOWLEDGEMENTS

This work was supported by the Fonds National Suisse de la Recherche Scientifique (grant no. 3100A0-100703).

REFERENCES

[1] Pierce KL, Premont RT, Lefkowitz RJ. Signalling: Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002; 3: 639-50.
[2] Benovic JL, Kuhn H, Weyand I, Codina J, Caron MG, Lefkowitz RJ. Functional desensitization of the isolated beta-adrenergic receptor kinase: potential role of an analog of the retinal arrestin. Proc Natl Acad Sci USA 1987; 84: 8879-82.
[3] Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu Rev Biochem 1998; 67: 653-92.
[4] Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. Beta-arrestin: a protein that regulates beta-adrenergic receptor function. Science 1990; 248: 1547-50.
[5] Goodman OB Jr, Krupnick JG, Santini F, et al. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 1996; 383(6659): 447-50.
[6] De Wire SM, Seungkift J, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. Annu Rev Physiol 2007; 69: 483-510.
[7] Angers S, Salahpour A, Bouvier M. Dimerization: an emerging concept for G-protein-coupled receptor ontology and function. Annu Rev Pharmacol Toxicol 2002; 42: 409-35.
[8] Moore CA, Milano SK, Benovic JL. Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 2007; 69: 451-82.
[9] Gurevich VV, Gurevich EV. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol & Therapeutics 2006; 110: 465-502.
[10] Shiina T, Kawasaki A, Nagao T, Kurose H. Interaction with beta-arrestin determines the difference in internalization behavior between beta1- and beta2-adrenergic receptors. J Biol Chem 2000; 275(37): 29082-90.
[11] Tilley DG, Kim IM, Patel PA, Violin JD, Rockman HA. Beta-arrestin mediates beta1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. J Biol Chem 2009; 284(30): 20735-86.
[12] Nantel F, Bonin H, EmoriQ LI, et al. The human beta 3-adrenergic receptor is resistant to short agonist-promoted desensitization. Mol Pharmacol 1993; 43: 548-55.
[13] Cao W, Luttrell LM, Medvedev AV, et al. Direct binding of activated e-Src to the beta 3-adrenergic receptor is required for MAP kinase activation. J Biol Chem 2000; 275(49): 38131-4.
[14] DeGralla JL, Gagnon AW, Benovic JL, Orsini MJ. Role of arrestins in endocytosis and signaling of alpha2-adrenergic receptor subtypes. J Biol Chem 1999; 274(16):11253-9.
[15] DeGralla JL, Gurevich VV, Benovic JL. The third intracellular loop of alpha 2-adrenergic receptors determines subtype specificity of arrestin interaction. J Biol Chem 2002; 277(45): 43247-52.
[16] Stanasila L, Abuin L, Delpón E, Caballero R, et al. Regulation of receptor interaction with beta-arrestins and AP50. Mol Pharmacol 2008; 74: 562-73.
[17] Tang Y, Hu LA, Miller WE, et al. Identification of the endophilins (SH3/p4/p13) as novel binding partners for the beta 1-adrenergic receptor. Proc Natl Acad Sci USA 1999; 96(22): 12559-64.
[18] Hu LA, Tang Y, Miller WE, et al. Beta1-adrenergic receptor association with PSD-95. Inhibition of receptor internalization and facilitation of beta 1-adrenergic receptor interaction with N-methyl-D-aspartate receptors. J Biol Chem 2000; 275(49): 38659-66.
[19] Hu LA, Chen W, Premont RT, Cong M, Lefkowitz RJ. G protein-coupled receptor kinase 5 regulates beta 1-adrenergic receptor association with PSD-95. J Biol Chem 2002; 277(2): 1607-13.
[20] Xu J, Paquet AS, Wood JD, Ross CA, Hall RA. Beta1-adrenergic receptor association with the synaptic scaffolding protein membrane-associated guanylate kinase inverted-2 (MAGI-2). Differential regulation of receptor internalization by MAGI-2 and PSD-95. J Biol Chem 2001; 276(44): 41310-7.
[21] Hu LA, Chen W, Martin NP, Whalen EJ, Premont RT, Lefkowitz RJ. GPCR interacts with the beta1-adrenergic receptor and regulates beta1-adrenergic receptor-mediated ERK activation. J Biol Chem 2003; 278(28): 26295-301.
[22] He J, Bellini M, Xu J, Castelberry AM, Hall RA. Interaction with cystic fibrosis transmembrane conductance regulator-associated ligand (CAL) inhibits beta1-adrenergic receptor surface expression. J Biol Chem 2004; 279(48): 50190-6.
[23] Pak Y, Pham N, Rotin D. Direct binding of the beta adrenergic receptor to the cyclic AMP-dependent guanine nucleotide exchange factor CnrasGEF leads to Ras activation. Mol Cell Biol 2002; 22(22): 7942-52.
[24] Xiang Y, Devic E, Kublika B. The PDZ binding motif of the beta 1 adrenergic receptor modulates receptor trafficking and signaling in cardiac myocytes. J Biol Chem 2002; 277(37): 33783-90.
[25] He J, Bellini M, Inuzuka H, et al. Proteomic analysis of beta1-adrenergic receptor interactions with PDZ scaffold proteins. J Biol Chem 2006; 281(5): 2820-7.
[26] Heydorn A, Søndergaard BP, Ersbøll B, et al. A library of 7TM receptors expressed in L2.1 mast cells: identification of a novel G protein-coupled receptor. J Biol Chem 2002; 277(37): 33783-90.
[27] Abu-Helou A, Simonian F. Identification and biological significance of G-protein-coupled receptor associated sorting proteins (GASPs). Pharmacol & Therapeutics 2010; 127(2): 245-70.
[28] Hicks SW, Horn TA, McCaffrey JM, Zacherman DM, Machamer CE. Golgin-160 promotes cell surface expression of the beta1-adrenergic receptor. Traffic 2006; 7(12): 1666-77.
[29] Tutor AS, Delplon E, Caballero R, et al. Association of 14-3-3 proteins to beta1-adrenergic receptors modulates Kv11.1 K+ channel activity in recombinant systems. Mol Biol Cell 2006; 17: 4666-74.
Richter W, Day P, Agrawal R, et al. Signaling from beta1- and beta2-adrenergic receptors is defined by differential interactions with PDE4. EMBO J 2008; 27(2): 384-93. beta2

Hall RA, Premont RT, Chow CW, et al. The beta2-adrenergic receptor interacts with the Na+/H+ exchanger regulatory factor to control Na+/H+ exchange. Nature 1998; 392(6676): 626-30.

Weinman EJ, Hall RA, Friedman PA, Liu-Chen LY, Shenolikar S. The association of NHERF adaptor proteins with g protein-coupled receptors and receptor tyrosine kinases. Annu Rev Physiol 2006; 68: 491-505.

Maudsley S, Zamah AM, Rahman N, et al. Platelet-derived growth factor receptor association with Na(+)/H(+)-exchanger regulatory factor potentiates receptor activity. Mol Cell Biol 2000; 20(22): 8352-63.

Naren AP, Cobb B, Li C, et al. A macromolecular complex of beta 2 adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA. Proc Natl Acad Sci USA 2003; 100(1): 342-6.

Cao TT, Deacon HW, Reczek D, Bretscher A, von Zastrow M. A kinase-regulated PDZ-domain interaction controls endocytic sorting of the beta2-adrenergic receptor. Nature 1999; 401(6750): 286-90.

Cong M, Perry SJ, Hu LA, Hanson PI, Cl/aing A, Letkowitz RJ. Binding of the beta2 adrenergic receptor to N-ethylmaleimidesensitive factor regulates receptor recycling. J Biol Chem 2001; 276(48): 45145-52.

Xiang Y, Kobiklia B. The PDZ-binding motif of the beta2-adrenoceptor is essential for physiologic signaling and trafficking in cardiac myocytes. Proc Natl Acad Sci USA 2003; 100(19): 10776-81.

Lin F, Wang H, Malbon CC. Gravin-mediated formation of signaling complexes in beta 2 adrenergic receptor desensitization and resensitization. J Biol Chem 2000; 275(25): 19025-34.

Fan G, Shumay E, Wang H, Malbon CC. The scaffold protein gravin (cAMP-dependent protein kinase-anchoring protein 250) binds the beta 2-adrenergic receptor via the receptor cytoplasmic Arg-329 to Leu-413 domain and provides a mobile scaffold during desensitization. J Biol Chem 2001; 276(16): 13240-7.

Fraser ID, Cong M, Kim J, et al. Assembly of an A kinase-anchoring protein-beta(2)-adrenergic receptor complex facilitates receptor phosphorylation and signaling. Curr Biol 2000; 10(7): 409-12.

Cong M, Perry SJ, Lin FT, et al. Regulation of membrane targeting of the G protein-coupled receptor kinase 2 by protein kinase A and its anchoring protein AKA079. J Biol Chem 2001; 276(18): 15192-9.

Shih M, Malbon CC. Serum and insulin induce a Grb2-dependent shift in agonist affinity of beta-adrenergic receptors. Cell Signal 1998; 10(8): 575-82.

Karoor V, Wang L, Wang HY, Malbon CC. Insulin stimulates sequestration of beta-adrenergic receptors and enhanced association of beta-adrenergic receptors with Grb2 via tyrosine 350. J Biol Chem 1998; 273(49): 33035-41.

Davare MA, Avdonin V, Hall DD, et al. A beta2 adrenergic receptor signaling complex assembled with the Ca2+ channel Cav1.2. Science 2001; 293(5527): 98-101.

Liu G, Shi J, Yang L, et al. Assembly of a Ca2+-dependent BK channel signaling complex by binding to beta2 adrenergic receptor. EMBO J 2004; 23(11): 2196-205.

Xie L, Xiao K, Whalen EJ, et al. Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitination by pVHL. Sci Signal 2009; 2(78): 1-9.

Papo AS, Minneman KP. Interaction of neuronal nitric oxide synthase with alpha1-adrenergic receptor subtypes in transfected HEK-293 cells. BMC Pharmacol 2002; 2: 17.

Xu Q, Xu N, Zhang T, et al. Mammalian tolloid alters subcellular localization, internalization, and signaling of alpha1a-adrenergic receptors. Mol Pharmacol 2006; 70(2): 532-41.

Hague C, Bernstein LS, Ramini S, Chen Z, Minneman KP, Hepler JR. Selective inhibition of alpha1a-adrenergic receptor signaling by RGS2 association with the receptor third intracellular loop. J Biol Chem 2005; 280: 27289-95.

Bernstein LS, Ramini S, Hague C, et al. RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate Gq11alpha signalling. J Biol Chem 2004; 279(20): 21248-56.

Diviani D, Lattion AL, Abuin L, Staub O, Coteechia S. The adaptor complex 2 directly interacts with the alpha1b-adrenergic receptor and plays a role in receptor endocytosis. J Biol Chem 2003; 278: 19331-340.

Stanasila L, Abuin L, Diviani D, Coteechia S. Direct interaction of the alpha1b-adrenergic receptor with the alpha1b-adrenergic receptor mediates recycling of the internalized receptors. J Biol Chem 2006; 281: 4354-63.

Pupo AS, Minneman KP. Specific interactions between g14Q and alpha1-adrenergic receptor subtypes. J Recept Signal Transduct Res 2003; 23(2-3): 185-95.

Chen Z, Hague C, Hall RA, Minneman KP. Syntrophins regulate alpha1D-adrenergic receptors through a PDZ-domain-mediated interaction. J Biol Chem 2006; 281(18): 12441-20.

Prezeau L, Richman JG, Edwards SW, Limbird LE. The zeta isoform of 14-3-3 proteins interacts with the third intracellular loop of different alpha2-adrenergic receptor subtypes. J Biol Chem 2002; 277: 50589-96.

Wang Q, Limbird LE. Regulated interactions of the alpha 2A adrenergic receptor with spinophilin, 14-3-3-zeta, and arrestin 3. J Biol Chem 2002; 277(52): 50589-96.

Richman JG, Brady AE, Wang Q, Hensel JL, Colbran RJ, Limbird LE. Agonist-regulated Interaction between alpha2-adrenergic receptors and spinophilin. J Biol Chem 2001; 276(18): 15003-8.

Wang Q, Limbird LE. Regulation of alpha2AR trafficking and signaling by interacting proteins. Biochem Pharmacol 2007; 73(8): 1135-45.

Brady AE, Wang Q, Colbran RJ, Allen PB, Greengard P, Limbird LE. Spinophilin stabilizes cell surface expression of alpha 2B-adrenergic receptors. J Biol Chem 2003; 278(34): 32405-12.

Wang Q, Zhao J, Brady AE, et al. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science 2004; 304(5679): 1940-4.

Wang X, Zeng W, Kim MS, Allen PB, Greengard P, Mualllem S. Spinophilin/nuernabin reciprocally regulate signaling intensity by G protein-coupled receptors. EMBO J 2007; 26(11): 2768-76.

Weber B, Schaper C, Wang Y, Scholz J, Bein B. Interaction of the ubiquitin carboxylterminal esterase L1 with alpha2-adrenergic receptors inhibits agonist-mediated p44/42 MAP kinase activation. Cell Signal 2009; 21(10): 1513-21.

Hebert TE, Moffett S, Morello JP, et al. A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 1996; 271(27): 16384-92.

Angers S, Salahpour A, Joly E, et al. Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci USA 2000; 97(7): 3684-9.

Mercier JF, Salahpour A, Angers S, Breit A, Bouvier M. Quantitative assessment of beta 1 and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J Biol Chem 2002; 277(47): 44925-31.

Stanasila I, Perez JB, Vogel H, Coteechia S. Oligomerization of the alpha1a- and alpha1b-adrenergic receptor subtypes: potential implications in receptor internalization. J Biol Chem 2003; 278: 40239-51.

Uberti MA, Hall RA, Minneman KP. Subtype-specific dimerization of alpha 1-adrenoceptors: effects on receptor expression and pharmacological properties. Mol Pharmacol 2003; 64(6): 1379-90.

Small KM, Schwarb MR, Glinka C, et al. Alpha2A- and alpha2C-adrenergic receptors form homo- and heterodimers: the heterodimeric state impairs agonist-promoted GRK phosphorylation and beta-arrestin recruitment. Biochemistry 2006; 45(13): 4760-7.

Zhou F, Filipceanu CM, Duverney MT, Wu G. Cell-surface targeting of alpha2-adrenergic receptors --- inhibition by a transport deficient mutant through dimerization. Cell Signal 2006; 18(3): 318-27.

Gouldson PR, Snell CR, Bywater RP, Higgs C, Reynolds CA. Domain swapping in G-protein coupled receptor dimers. Protein Eng 1998; 11(12): 1181-93.

Carrillo JJ, Leppez-Giménez JF, Milliga S, Multiple interactions between transmembrane helices generate the oligomeric alpha1b-adrenoceptor. Mol Pharmacol 2004; 66(5): 1123-37.

Salahpour A, Angers S, Mercier JF, Lagacé M, Marullo S, Bouvier M. Homodimerization of the beta2-adrenergic receptor as a
prerequisite for cell surface targeting. J Biol Chem 2004; 279(32): 33390-7.

[73] Cao TT, Brelot A, von Zastrow M. The composition of the beta-2 adrenergic receptor oligomer affects its membrane trafficking after ligand-induced endocytosis. Mol Pharmacol 2005; 67(1): 288-97.

[74] Laviose C, Mercier JF, Salahpour A, et al. Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem 2002; 277(38): 35402-10.

[75] Breit A, Lagacé M, Bouvier M. Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J Biol Chem 2004; 279(27): 28756-65.

[76] Hague C, Uberti MA, Chen Z, Hall RA, Minneman KP. Cell surface expression of alpha1D-adrenergic receptors is controlled by heterodimerization with alpha1B-adrenergic receptors. J Biol Chem 2004; 279(15): 15541-9.

[77] Uberti MA, Hague C, Oller H, Minneman KP, Hall RA. Heterodimerization with beta2-adrenergic receptors promotes surface expression and functional activity of alpha1D-adrenergic receptors. J Pharmacol Exp Ther 2005; 313(1): 16-23.

[78] Xu J, He J, Castleberry AM, Balasubramanian S, Lau AG, Hall RA. Heterodimerization of alpha 2A- and beta 1-adrenergic receptors. J Biol Chem 2003; 278(12): 10770-7.

[79] Prinster SC, Holmqvist TG, Hall RA. Alpha2C-adrenergic receptors exhibit enhanced surface expression and signaling upon association with beta2-adrenergic receptors. J Pharmacol Exp Ther 2006; 318(3): 974-81.

[80] Hague C, Uberti MA, Chen Z, et al. Olfactory receptor surface expression is driven by association with the beta2-adrenergic receptor. Proc Natl Acad Sci USA 2004; 101(37): 13672-6.

[81] Jordan BA, Trapizade N, Gomes I, Nivarthi R, Devi LA. Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci USA 2001; 98(1): 343-8.

[82] Barki-Harrington L, Luttrel LM, Rockman HA. Dual inhibition of beta-adrenergic and angiotensin II receptors by single antagonist. Circulation 2003; 108: 1611-8.

[83] Berthouze M, Ayoub M, Russo O, et al. Constitutive dimerization of human serotonin 5HT4 receptors in living cells. FJ Biol Chem 2005; 579: 2973-80.

[84] McGraw DW, Mihlbachler KA, Schwarb MR, et al. Airway smooth muscle prostaglandin-E2 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J Biol Chem 2006; 278(5): 400-9.

[85] Hudson BD, Hebter TE, Kelly MEM. Physical and functional interaction of CB1 cannabinoid receptors and beta2-adrenergic receptors. Br J Pharmacol 2010; 160: 627-42.

[86] Jordan BA, Gomes I, Rios C, Filipovska J, Devi LA. Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol Pharmacol 2003; 64(6): 1317-24.

[87] Rios C, Gomes I, Devi LA. Interactions between alpha opioid receptors and alpha-adrenergic receptors. Clin Exp Pharmacol Physiol 2004; 31(11): 833-6.

[88] Joiner ML, Lisé MF, Yuen EY, et al. Assembly of a beta2-adrenergic receptor–GluR1 signalling complex for localised cAMP signalling. EMBO J 2010; 29(2): 482-95.

[89] Dev KK. Making protein interactions druggable: targeting the PDZ domains. Nat Rev Drug Discov 2004; 3: 1047-56.

[90] Ritter SL, Hall RA. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat Rev Mol Cell Biol 2009; 10: 819-30.

PMID: 21777184